Key Points
- Intellia Therapeutics EVP Edward Dulac III sold 4,677 shares on July 2 at an average price of $18.00, totaling about $84,186. After the sale, he still held 156,286 shares.
- NTLA shares were down 2.6% in the session, opening at $17.38. The stock has traded between a 52-week low of $7.95 and high of $28.25.
- Analysts remain mixed on the stock, with a consensus rating of “Hold” and an average price target of $20.46. Recent targets ranged from $12 to $49, reflecting wide disagreement on NTLA’s outlook.
Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) CAO Michael Dube sold 2,641 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the sale, the chief accounting officer directly owned 66,886 shares of the company's stock, valued at approximately $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Intellia Therapeutics Price Performance
NTLA stock opened at $17.09 on Tuesday. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $28.25. The stock has a market capitalization of $2.39 billion, a price-to-earnings ratio of -4.84 and a beta of 1.77. The business's fifty day moving average price is $14.17 and its two-hundred day moving average price is $13.13.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.11. The business had revenue of $15.05 million during the quarter, compared to analysts' expectations of $13.81 million. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.During the same period in the previous year, the company posted ($1.10) earnings per share. Research analysts expect that Intellia Therapeutics, Inc. will post -3.18 EPS for the current year.
Institutional Investors Weigh In On Intellia Therapeutics
Several hedge funds have recently modified their holdings of NTLA. AQR Capital Management LLC raised its position in Intellia Therapeutics by 154.1% in the first quarter. AQR Capital Management LLC now owns 90,875 shares of the company's stock valued at $646,000 after purchasing an additional 55,118 shares during the last quarter. Woodline Partners LP acquired a new position in shares of Intellia Therapeutics in the first quarter valued at approximately $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Intellia Therapeutics by 8.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company's stock valued at $3,709,000 after buying an additional 38,521 shares during the period. Creative Planning raised its holdings in Intellia Therapeutics by 12.9% in the 2nd quarter. Creative Planning now owns 33,102 shares of the company's stock valued at $310,000 after buying an additional 3,795 shares during the last quarter. Finally, Cetera Investment Advisers raised its holdings in Intellia Therapeutics by 47.4% in the 2nd quarter. Cetera Investment Advisers now owns 33,532 shares of the company's stock valued at $315,000 after buying an additional 10,785 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have commented on the stock. Truist Financial raised shares of Intellia Therapeutics to a "strong-buy" rating in a report on Wednesday, March 25th. HC Wainwright restated a "buy" rating and set a $25.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 15th. Canaccord Genuity Group restated a "buy" rating and set a $49.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, June 16th. New Street Research set a $25.00 target price on Intellia Therapeutics in a report on Monday, June 15th. Finally, Citigroup reiterated a "market outperform" rating on shares of Intellia Therapeutics in a research note on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $20.46.
Get Our Latest Analysis on NTLA
Intellia Therapeutics Company Profile
(
Get Free Report)
Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.
Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
